CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5403-5408

  Shen, Bo ^a   Zheng, Ma Qing ^b   Lu, Jian Wei ^a   Jiang, Qian ^a   Wang, Tai Hong ^a   Huang, Xin En ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

AMD3100; CXCL12; CXCR4; Invasion; Pancreatic cancer; Proliferation

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; GELATINASE A; GELATINASE B; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; RECOMBINANT PROTEIN; STROMAL CELL DERIVED FACTOR 1; UROKINASE;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL12; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84887602851     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5403     Document Type: Article

References (67)

1. Almofti A, Uchida D, Begum NM, et al (2004). The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol, 25, 65-71.
2. Balkwill F (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol, 14, 171-9.
3. Blanco J, Barretina J, Henson G, et al (2000). The CXCR4 antagonistAMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob Agents Chemother, 44, 51-56.
4. Chen G, Shen ZL, Wang L, et al (2013). Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pac J Cancer Prev, 14, 3871-5.
5. Chen GS, Yu HS, Lan CC, et al (2006). CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol, 154, 910-8.
6. Cheng Z, Zhou S, Wang X, et al (2009). Characterization and application of two novel monoclonal antibodies against human CXCR4: cell proliferation and migration regulation for glioma cell line in vitro by CXCR4/SDF-1 alpha signal. Hybridoma (Larchmt), 28, 33-41.
7. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
8. Demetter P, Maréchal R, Verset L, et al (2012). Molecular changes in pancreatic cancer: implications for molecular targeting therapy. Acta Gastroenterol Belg, 75, 210-4.
9. Deng QQ, Huang XE, Ye LH, et al (2013).Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.
10. Dömötör A, Peidl Z, Vincze A, et al (2005). Immunohisto-chemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology, 13, 161-77.
11. Durlik M, Gardian K (2012). Metalloproteinase 2 and 9 activity in the development of pancreatic cancer. Pol Przegl Chir, 84, 377-82.
12. Fernadis AZ, Cherla RP, Ganju RK (2003). Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45. J Biol Chem, 278, 9536-43.
13. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
14. Ghosh S, Preet A, Groopman JE, Ganju RK (2006). Cannabinoid receptor CB2 modulates the CXCL12-CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol, 43, 2169-9.
15. Gong P, Huang XE, Chen CY, et al (2012). Comparison on Complications of Peripherally Inserted Central Catheters by Ultrasound Guide or Conventional Method in Cancer Patients. Asian Pac J Cancer Prev, 13, 1873-5.
16. Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS (2011). Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res, 9, 377-89.
17. Grzesiak JJ, Smith KC, Burtom DW, Deftos LJ, Michael bouvet (2007). Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery, 141, 804-14.
18. Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91.
19. Guo L, Cui ZM, Zhang J, Huang Y (2011). Chemokine axes CXCL12-CXCR4 and CXCL16/CXCR6 correlation with lympnode metastasis in epithelial ovarian carcinoma. Chin J Cancer, 30, 336-343.
20. Hidalgo M (2010). Pancreatic cancer. N Engl J Med, 362, 1605-17.
21. Horuk R (2001). Chemokine receptors. Cytokine Growth Factor Rev, 12, 313-35.
22. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
23. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4.
24. Kato M, Kitayama J, Kazama S, Nagawa H (2003). Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res, 5, R144-50.
25. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY (2005). CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther, 12, 84-9.
26. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
27. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of Irinotecan plus Nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
28. Li CG, Huang XE, Xu L, et al (2012). Clinical Application of Serum Tumor Associated Material (TAM) from Non-small Cell Lung Cancer Patients. Asian Pac J Cancer Prev, 13, 301-4.
29. Li JK, Yu L, Shen Y, et al (2008). Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol, 14, 2308-13.
30. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
31. Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on Safety and Efficacy of Yadanzi® (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer. Asian Pac J Cancer Prev, 14, 2009-12.
32. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.
33. Liu YC, Zhou SB, Gao F, et al (2013). Phase II study on breast conservative surgery plus chemo-and radiotherapy in treating Chinese patients with early staged breast cancer. Asian Pac J Cancer Prev, 14, 3747-50.
34. Liu YC, Zhou SB, Gao F, et al (2013).Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.
35. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.
36. Lukacs NW, Berlin A, Schols D, Skerlj RT, Brideger GJ (2002). AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol, 160, 1353-60.
37. Moll NM, Ransohoff RM (2010). CXCL12 and CXCR4 in bone marrow physiology. Expert Rev Hematol, 3, 315-22.
38. Muller A, Sonkoly E, Eulert C, et al (2006). Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer, 118, 2147-57.
39. Nagasawa T, Hirota S, Tachibana K, et al (1996). Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-l. Nature, Patrussi L, Baldari CT (2011). The CXCL12-CXCR4 axis as a therapeutic target in cancer and HIV-1 infection. Curr Med Chem, 18, 497-512.
40. Pitcher J, Shimizu S, Burbassi S, Meucci O (2010). Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS. J Neuroimmunol, 224, 66-71.
41. Ravi D, Ramadas K, Mathew BS, et al (1998). Angiogenesis during tumor progression in the oral canity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol, 34, 543-8.
42. Salvatore P, Pagliarulo C, Colicchio R, Napoli C (2010). CXCR4-CXCL12-dependent inflammatory network and endothelial progenitors. Curr Med Chem, 17, 3019-29.
43. Scotton CJ, Wilson JL, Scott K, et al (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res, 62, 5930-8.
44. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.
45. Stathis A, Moore MJ (2010). Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol, 7, 163-72.
46. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52.
47. Tashiro K, Tada H, Heilker R, et al (1993). Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science, 261, 600-3.
48. Terasaki M, Sugita Y, Arakawa F, et al (2011). CXCL12-CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol, 28, 89-97.
49. Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6.
50. Wu X, Lee VC, Chevalier E, Hwang ST (2009). Chemokine receptors as targets for cancer therapy. Curr Pharm Des, 15, 742-57.
51. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.
52. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
53. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
54. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
55. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
56. Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.
57. Yamamoto H, Itoh F, Iku S, et al (2001). Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol, 19, 1118-27.
58. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
59. Yang L, Huang XE, Zhou JN (2013). Risk assessment on anastomotic leakage after rectal cancer surgery: an analysis of 753 patients. Asian Pac J Cancer Prev, 14, 4447-53.
60. Yin HT, Tian QZ, Guan L (2013).In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6.
61. Yin HT, Zhang DG, Wu XL(2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12.
62. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
63. Zhan YP, Huang XE, Cao J et al (2012). Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6.
64. Zhan YP, Huang XE, Cao J, et al (2012). Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21.
65. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
66. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
67. Zhong W, Chen W, Zhang D, et al (2012). CXCL12-CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: A clinical study. Exp Ther Med, 4, 363-369.